Trial Profile
An Open-label Phase IIIb Study of Regorafenib in Patients With Metastatic Colorectal Cancer (CRC) Who Have Progressed After Standard Therapy
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 12 Dec 2022
Price :
$35
*
At a glance
- Drugs Regorafenib (Primary)
- Indications Adenocarcinoma; Colon cancer; Colorectal cancer; Rectal cancer
- Focus Adverse reactions; Expanded access; Registrational
- Acronyms CONSIGN
- Sponsors Bayer
- 24 Oct 2019 Trial has been completed in Netherlands, according to European Clinical Trials Database record.
- 15 Jun 2019 Trial has been completed in Belgium, Czech Republic, and Hungary, according to European Clinical Trials Database record.
- 13 Jun 2019 Trial has been completed in Sweden.